Gene and microRNA expression reveals sensitivity to paclitaxel in laryngeal cancer cell line

International Journal of Clinical and Experimental Pathology

Volumn 6, Issue 7, 2013, Pages 1351-1361

  Xu, Cheng Zhi ^a,b   Xie, Jin ^a   Jin, Bin ^a   Chen, Xin Wei ^a   Sun, Zhen Feng ^a   Wang, Bao Xing ^a   Dong, Pin ^a  

^a SHANGHAI FIRST PEOPLE S HOSPITAL   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Cell lines; Gene expression profiles; Laryngeal cancer; MiR expression profiles; Paclitaxel

Indexed keywords

ANTINEOPLASTIC AGENT; MICRORNA; PACLITAXEL; TUMOR MARKER;

ARTICLE; CELL LINES; CELL SURVIVAL; DNA MICROARRAY; DOSE RESPONSE; DRUG EFFECT; DRUG RESISTANCE; GENE EXPRESSION PROFILES; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IC 50; LARYNX CANCER; LARYNX TUMOR; METABOLISM; METHODOLOGY; MIR EXPRESSION PROFILES; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; TIME; TUMOR CELL LINE;

CELL LINES; GENE EXPRESSION PROFILES; LARYNGEAL CANCER; MIR EXPRESSION PROFILES; PACLITAXEL;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITORY CONCENTRATION 50; LARYNGEAL NEOPLASMS; MICRORNAS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PACLITAXEL; REAL-TIME POLYMERASE CHAIN REACTION; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84882956514     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Myers EN. Cancer of the head and neck. Philadelphia, Pa.: Saunders, 2003.
2. Schrijvers D and Vermorken JB. Role of taxoids in head and neck cancer. Oncologist 2000; 5: 199-208.
3. Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, Glisson B, Trotti A, Ridge JA, Chao C, Peters G, Lee DJ, Leaf A, Ensley J and Cooper J. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003; 349: 2091-2098.
4. Pfreundner L, Hoppe F, Willner J, Preisler V, Bratengeier K, Hagen R, Helms J and Flentje M. Induction chemotherapy with paclitaxel and cisplatin and CT-based 3D radiotherapy in patients with advanced laryngeal and hypopharyngeal carcinomas--a possibility for organ preservation. Radiother Oncol 2003; 68: 163-170.
5. Machtay M, Rosenthal DI, Hershock D, Jones H, Williamson S, Greenberg MJ, Weinstein GS, Aviles VM, Chalian AA, Weber RS and Penn Cancer Center Clinical Trials G. Organ preservation therapy using induction plus concurrent chemoradiation for advanced resectable oropharyngeal carcinoma: a University of Pennsylvania Phase II Trial. J Clin Oncol 2002; 20: 3964-3971.
6. Schrijvers D and Vermorken JB. Taxanes in the treatment of head and neck cancer. Curr Opin Oncol 2005; 17: 218-224.
7. Cmelak AJ, Murphy BA, Burkey B, Douglas S, Shyr Y and Netterville J. Taxane-based chemoirradiation for organ preservation with locally advanced head and neck cancer: results of a phase II multi-institutional trial. Head Neck 2007; 29: 315-324.
8. Cmelak AJ, Li S, Goldwasser MA, Murphy B, Cannon M, Pinto H, Rosenthal DI, Gillison M and Forastiere AA. Phase II trial of chemoradiation for organ preservation in resectable stage III or IV squamous cell carcinomas of the larynx or oropharynx: results of Eastern Cooperative Oncology Group Study E2399. J Clin Oncol 2007; 25: 3971-3977.
9. Rosell R, Scagliotti G, Danenberg KD, Lord RV, Bepler G, Novello S, Cooc J, Crino L, Sanchez JJ, Taron M, Boni C, De Marinis F, Tonato M, Marangolo M, Gozzelino F, Di Costanzo F, Rinaldi M, Salonga D and Stephens C. Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer. Oncogene 2003; 22: 3548-3553.
10. Verrills NM, Po'uha ST, Liu ML, Liaw TY, Larsen MR, Ivery MT, Marshall GM, Gunning PW and Kavallaris M. Alterations in gamma-actin and tubulin-targeted drug resistance in childhood leukemia. J Natl Cancer Inst 2006; 98: 1363-1374.
11. Dan S, Tsunoda T, Kitahara O, Yanagawa R, Zembutsu H, Katagiri T, Yamazaki K, Nakamura Y and Yamori T. An integrated database of chemosensitivity to 55 anticancer drugs and gene expression profiles of 39 human cancer cell lines. Cancer Res 2002; 62: 1139-1147.
12. Ahmed AA, Mills AD, Ibrahim AE, Temple J, Blenkiron C, Vias M, Massie CE, Iyer NG, McGeoch A, Crawford R, Nicke B, Downward J, Swanton C, Bell SD, Earl HM, Laskey RA, Caldas C and Brenton JD. The extracellular matrix protein TGFBI induces microtubule stabilization and sensitizes ovarian cancers to paclitaxel. Cancer Cell 2007; 12: 514-527.
13. Cochrane DR, Spoelstra NS, Howe EN, Nordeen SK and Richer JK. MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agen-ts. Mol Cancer Ther 2009; 8: 1055-1066.
14. Fujita Y, Kojima K, Ohhashi R, Hamada N, Nozawa Y, Kitamoto A, Sato A, Kondo S, Kojima T, Deguchi T and Ito M. MiR-148a attenuates paclitaxel resistance of hormone-refractory, drug-resistant prostate cancer PC3 cells by regulating MSK1 expression. J Biol Chem 2010; 285: 19076-19084.
15. Zhou M, Liu Z, Zhao Y, Ding Y, Liu H, Xi Y, Xiong W, Li G, Lu J, Fodstad O, Riker AI and Tan M. MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression. J Biol Chem 2010; 285: 21496-21507.
16. Ren Y, Zhou X, Mei M, Yuan XB, Han L, Wang GX, Jia ZF, Xu P, Pu PY and Kang CS. MicroRNA-21 inhibitor sensitizes human glioblastoma cells U251 (PTEN-mutant) and LN229 (PTEN-wild type) to taxol. BMC Cancer 2010; 10: 27.
17. Du L, Subauste MC, DeSevo C, Zhao Z, Baker M, Borkowski R, Schageman JJ, Greer R, Yang CR, Suraokar M, Wistuba II, Gazdar AF, Minna JD and Pertsemlidis A. miR-337-3p and its targets STAT3 and RAP1A modulate taxane sensitivity in non-small cell lung cancers. PLoS One 2012; 7: e39167.
18. Singh S, Chitkara D, Mehrazin R, Behrman SW, Wake RW and Mahato RI. Chemoresistance in prostate cancer cells is regulated by miRNAs and Hedgehog pathway. PLoS One 2012; 7: e40021.
19. Tusher VG, Tibshirani R and Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001; 98: 5116-5121.
20. Coser KR, Chesnes J, Hur J, Ray S, Isselbacher KJ and Shioda T. Global analysis of ligand sensitivity of estrogen inducible and suppressible genes in MCF7/BUS breast cancer cells by DNA microarray. Proc Natl Acad Sci U S A 2003; 100: 13994-13999.
21. Martinez N, Sanchez-Beato M, Carnero A, Moneo V, Tercero JC, Fernandez I, Navarrete M, Jimeno J and Piris MA. Transcriptional signature of Ecteinascidin 743 (Yondelis, Trabectedin) in human sarcoma cells explanted from chemo-naive patients. Mol Cancer Ther 2005; 4: 814-823.
22. Zhao Z, Liu Y, He H, Chen X, Chen J and Lu YC. Candidate genes influencing sensitivity and resistance of human glioblastoma to Semustine. Brain Res Bull 2011; 86: 189-194.
23. Fukuda N, Saitoh M, Kobayashi N and Miyazono K. Execution of BMP-4-induced apoptosis by p53-dependent ER dysfunction in myeloma and B-cell hybridoma cells. Oncogene 2006; 25: 3509-3517.
24. Ivanova T, Zouridis H, Wu Y, Cheng LL, Tan IB, Gopalakrishnan V, Ooi CH, Lee J, Qin L, Wu J, Lee M, Rha SY, Huang D, Liem N, Yeoh KG, Yong WP, Teh BT and Tan P. Integrated epigenomics identifies BMP4 as a modulator of cisplatin sensitivity in gastric cancer. Gut 2013; 62: 22-33.
25. Wahdan-Alaswad RS, Song K, Krebs TL, Shola DT, Gomez JA, Matsuyama S and Danielpour D. Insulin-like growth factor I suppresses bone morphogenetic protein signaling in prostate cancer cells by activating mTOR signaling. Cancer Res 2010; 70: 9106-9117.
26. Shajahan AN, Wang A, Decker M, Minshall RD, Liu MC and Clarke R. Caveolin-1 tyrosine phosphorylation enhances paclitaxel-mediated cytotoxicity. J Biol Chem 2007; 282: 5934-5943.
27. Bruning A, Burger P, Vogel M, Rahmeh M, Friese K, Lenhard M and Burges A. Bortezomib treatment of ovarian cancer cells mediates endoplasmic reticulum stress, cell cycle arrest, and apoptosis. Invest New Drugs 2009; 27: 543-551.
28. Delie F, Petignat P and Cohen M. GRP78-targeted nanotherapy against castrate-resistant prostate cancer cells expressing membrane GRP78. Target Oncol 2012; [Epub ahead of print].
29. Roongta UV, Pabalan JG, Wang X, Ryseck RP, Fargnoli J, Henley BJ, Yang WP, Zhu J, Madireddi MT, Lawrence RM, Wong TW and Rupnow BA. Cancer cell dependence on unsaturated fatty acids implicates stearoyl-CoA desaturase as a target for cancer therapy. Mol Cancer Res 2011; 9: 1551-1561.
30. Schlaepfer IR, Hitz CA, Gijon MA, Bergman BC, Eckel RH and Jacobsen BM. Progestin modulates the lipid profile and sensitivity of breast cancer cells to docetaxel. Mol Cell Endocrinol 2012; 363: 111-121.
31. Huntzinger E and Izaurralde E. Gene silencing by microRNAs: contributions of translational repression and mRNA decay. Nat Rev Genet 2011; 12: 99-110.
32. Yang L, Li N, Wang H, Jia X, Wang X and Luo J. Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycopro- tein-mediated drug resistance. Oncol Rep 2012; 28: 592-600.
33. Pan YZ, Gao W and Yu AM. MicroRNAs regulate CYP3A4 expression via direct and indirect targeting. Drug Metab Dispos 2009; 37: 2112-2117.
34. Yang X, Yin J, Yu J, Xiang Q, Liu Y, Tang S, Liao D, Zhu B, Zu X, Tang H and Lei X. miRNA-195 sensitizes human hepatocellular carcinoma cells to 5-FU by targeting BCL-w. Oncol Rep 2012; 27: 250-257.
35. Wang F, Liu M, Li X and Tang H. MiR-214 reduces cell survival and enhances cisplatin-induced cytotoxicity via down-regulation of Bcl2l2 in cervical cancer cells. FEBS Lett 2013; 587: 488-495.